The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ReGISTry Study of High Risk GIST Patients After Complete Resection:The adjuvant therapy and pathological diagnosis in Japan.
 
Toshirou Nishida
Honoraria - Bayer; Novartis; Pfizer
Research Funding - Bayer (Inst); Novartis (Inst)
 
Yuko Kitagawa
No Relationships to Disclose
 
Yukinori Kurokawa
Honoraria - Novartis
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Research Funding - Bayer; Novartis; Pfizer
 
Chikashi Ishioka
Speakers' Bureau - Asahi Kasei; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Toshihiko Doi
Honoraria - Chugai Pharma; Novartis
Consulting or Advisory Role - Amgen; Lilly; Merck Serono; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)
 
Yasuhide Yamada
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Dainippon Sumitomo Pharma; Novartis; Pfizer; Sumitomo Group; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Merck Serono (Inst); Novartis (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Masato Ozaka
No Relationships to Disclose
 
Haruhiko Cho
Honoraria - Novartis; Pfizer
 
Tetsuo Kanda
Consulting or Advisory Role - Novartis
 
Toshiro Sugiyama
No Relationships to Disclose
 
Akira Sawaki
Honoraria - Novartis; Pfizer
 
Yoshihiro Kakeji
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Toshihiro Hirai
No Relationships to Disclose
 
Shinji Hato
No Relationships to Disclose
 
Hideo Baba
No Relationships to Disclose
 
Kuniaki Shirao
No Relationships to Disclose
 
Seiichi Hirota
No Relationships to Disclose
 
Tatsuo Kagimura
No Relationships to Disclose